Mark Corrigan - 05 Oct 2026 Form 4 Insider Report for Wave Life Sciences, Inc. (WVE)

Reporting relationship: Director
Issuer ticker: WVE
Reported as of: 05 Oct 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 07 Oct 2026, 21:00:08 UTC
Prior SEC filing: 10 Dec 2025
Source filing: View source filing
Reporting owner signature: /s/ Mark Corrigan

Filing notes and source

Key filing fact

Mark Corrigan filed Form 4 for Wave Life Sciences, Inc. (WVE) on 07 Oct 2026.

Key facts

This page summarizes Mark Corrigan's Form 4 filing for Wave Life Sciences, Inc. (WVE).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 07 Oct 2026, 21:00.

Change

Previous filing in this sequence was filed on 10 Dec 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001250661 Primary reporting owner

CORRIGAN MARK

Relationship: Director
Address: C/O WAVE LIFE SCIENCES, INC.,, 733 CONCORD AVE., CAMBRIDGE
Signature: /s/ Mark Corrigan
Signature date: 07 Oct 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

WVE transaction

Common Stock

Award

Transaction value
Shares: +10,700
Change %: +37%
Price: $0.000000^*
Shares after: 39,515
Date: 05 Oct 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

WVE transaction Derivative

Stock Option (right to buy)

Award

Transaction value
Shares: +64,000
Change %
Price: $0.000000^*
Shares after: 64,000
Date: 05 Oct 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 64,000
Exercise price: $3.75
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The reporting person was granted this restricted stock unit award (RSU) pursuant to the 2026 Non-Employee Director Compensation Policy. The RSU vests as to 100% of the shares on the earlier of the Company's 2027 annual meeting of stockholders or October 5, 2027.

Footnote F2

The reporting person was granted this option pursuant to the 2026 Non-Employee Director Compensation Policy. The option vests as to 100% of the shares on the earlier of the Company's 2027 annual meeting of stockholders or October 5, 2027.

SEC remarks

On August 7, 2026, Wave Life Sciences, Inc., a Delaware corporation, became the successor of Wave Life Sciences Ltd., a company organized under the laws of the Republic of Singapore ("Wave-Singapore"), pursuant to a scheme of arrangement under Singapore law under which all issued ordinary shares in the capital of Wave-Singapore were exchanged on a one-for-one basis for shares of common stock of Wave Life Sciences, Inc. (the "Redomiciliation"). The Redomiciliation had the effect of changing Wave-Singapore's domicile, but did not alter the proportionate interests of securityholders. Exhibit 24.1 - Power of Attorney